UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
23.70
-0.06 (-0.25%)
Nov 17, 2025, 4:00 PM EST - Market closed
UroGen Pharma Employees
UroGen Pharma had 235 employees as of December 31, 2024. The number of employees increased by 34 or 16.92% compared to the previous year.
Employees
235
Change (1Y)
34
Growth (1Y)
16.92%
Revenue / Employee
$410,706
Profits / Employee
-$700,604
Market Cap
1.11B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 235 | 34 | 16.92% |
| Dec 31, 2023 | 201 | 1 | 0.50% |
| Dec 31, 2022 | 200 | 5 | 2.56% |
| Dec 31, 2021 | 195 | 8 | 4.28% |
| Dec 31, 2020 | 187 | 14 | 8.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
URGN News
- 11 days ago - UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 11 days ago - UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum - GlobeNewsWire
- 11 days ago - UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial - GlobeNewsWire
- 13 days ago - UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire
- 15 days ago - UroGen: Expect Rough Patch Before Strong Recovery In 2026 - Seeking Alpha
- 18 days ago - UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 - GlobeNewsWire
- 21 days ago - Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026 - GlobeNewsWire
- 6 weeks ago - ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer - GlobeNewsWire